Group 1: Company Developments - Yuan Da Pharmaceutical (00512.HK) announced that its partner, Taisun Pharmaceutical, successfully completed Phase II and III clinical trials for APP13007, a hormone nano-suspension eye drop, which showed significant efficacy in treating postoperative inflammation and pain [1] - Junshi Biosciences (688180.SH) reported that its PARP inhibitor, senaparib, achieved the primary endpoint in a Phase III clinical trial for advanced ovarian cancer, and plans to submit a new drug application soon [4] - Zhongyuan Jianye (09982.HK) successfully held a signing ceremony for 21 projects in Henan, with a total contracted construction area of approximately 1.9515 million square meters [5] Group 2: Sales and Financial Performance - Qiu Tai Technology (01478.HK) disclosed that it sold 37.928 million camera modules in March 2023, a month-on-month increase of 41.8%, but a year-on-year decrease of 2% [2] - China Resources Land (01109.HK) reported a total contract sales amount of approximately RMB 38.8 billion in March 2023, representing a year-on-year increase of 85.7% [3] - Far East Horizon (02163.HK) achieved a revenue of HKD 36.97 million in the first quarter, reflecting a year-on-year growth of 9.41% [7] Group 3: Market and Operational Data - China Metallurgical Group (01618.HK) signed new contracts worth RMB 325.81 billion from January to March 2023, marking a year-on-year increase of 2.1% [8] - Longyuan Power (00916.HK) completed a total power generation of 19.6033 million MWh in the first quarter, a year-on-year increase of 7.61% [8] - MONGOL MINING (00975.HK) sold 1.6 million tons of washed coking coal products in the first quarter, a year-on-year increase of 343% [8]